1. Pink Sheet
  2. >>Agency Leadership
  3. >>US FDA

NASH Drug Development Questions? US FDA Has Many Of The Answers

 
• By Brenda Sandburg

From biomarkers to treatment effect size, agency officials respond to some of more than a hundred questions that poured in during a webinar on development of drugs to treat the liver disease.

Liver
FDA officials address questions about development of drugs for NASH liver disease • Source: Shutterstock

The US Food and Drug Administration was deluged with questions during a webinar on the development of new drugs to treat non-alcoholic steatohepatitis (NASH), showing how hot the area is in pharma R&D and the issues of concern to sponsors, from the use of biomarkers to the length of trials.

In opening the 29 January webinar, Toru Matsubayashi, a medical reviewer in the Division of Hepatology and Nutrition, noted some...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

US FDA Appears To Be Managing MAHA Well By Feeding Instead Of Receiving Priorities

 
• By Ramsey Baghdadi

The newly issued Make America Healthy Again strategy report suggests that FDA leaders are doing a good job of feeding ideas to the Trump Administration, rather than having the agency agenda dictated from above.

US FDA May Ask Sponsors To Share Data To Help Train AI

 
• By Michael McCaughan

The US FDA may ask sponsors for permission to train AI models using data from new drug applications. Alternatives to animal testing could be a test case.

‘Major Statements’ Are Major Target Of US FDA’s New TV Ad Crackdown

 
• By Sarah Karlin-Smith, Cathy Kelly, and Derrick Gingery

The bolus of untitled letters signals the FDA's approach to enforcement of the final rule on the presentation of the major statement in direct-to-consumer TV ads in a clear, conspicuous and neutral matter.

Why ACIP Could Get Away With Unscientific Actions US FDA Cannot

 
• By Sarah Karlin-Smith

The CDC and its Advisory Committee on Immunization Practices reportedly are planning to make unsubstantiated claims about COVID-19 vaccine adverse events with little recourse for manufacturers and other stakeholders.

More from Agency Leadership

‘Major Statements’ Are Major Target Of US FDA’s New TV Ad Crackdown

 
• By Sarah Karlin-Smith, Cathy Kelly, and Derrick Gingery

The bolus of untitled letters signals the FDA's approach to enforcement of the final rule on the presentation of the major statement in direct-to-consumer TV ads in a clear, conspicuous and neutral matter.

Why ACIP Could Get Away With Unscientific Actions US FDA Cannot

 
• By Sarah Karlin-Smith

The CDC and its Advisory Committee on Immunization Practices reportedly are planning to make unsubstantiated claims about COVID-19 vaccine adverse events with little recourse for manufacturers and other stakeholders.

Emer Cooke’s EMA Leadership Extended Until 2027 Ahead Of Planned Retirement

 
• By Eliza Slawther

The European Medicines Agency’s executive director Emer Cooke will remain in her post until April 2027, a shorter timeframe than the full five-year term for an executive director’s mandate at the agency, as she will be due to retire.